Table 1.
Patient characteristics
| Variables | |
|---|---|
| Age, mean (s.d.), years | 61 (10) |
| Aged >61 years, n (%) | 63 (46) |
| Race (Caucasian), n (%) | 127 (93) |
| BMI, median (IQR), kg/m2 | 26 (23–30) |
| DMARDs (yes), n (%) | 118 (86) |
| Smoking, median (IQR), pack-years | 1 (0–17) |
| High glucocorticoid usea, n (%) | 41 (30) |
| No history of glucocorticoid use, n (%) | 41 (30) |
| Current osteoporosis medication use, n (%) | 19 (14) |
| Disease duration, median (IQR), years | 13 (7–23) |
| Early RAb, n (%) | 26 (19) |
| Seropositive (RF and/or anti-CCP), n (%) | 105 (76) |
| RF status positive, n (%) | 88 (64) |
| Anti-CCP positive, n (%) | 87 (63) |
| MDHAQ score, median (IQR) | 0.6 (0.2–1.0) |
| DAS28, median (IQR) | 3.7 (2.5–4.9) |
| Time difference, median (IQR), monthsc | 7 (1–14) |
| Hand DXR-BMD, mean (s.d.), g/cm2 | 0.52 (0.09) |
| Total hip DXA, mean (s.d.), g/cm2 | 0.85 (0.11) |
| Lumbar spine DXA, mean (s.d.), g/cm2 | 0.97 (0.16) |
Lumbar spine BMD analysis consisted of 129 patients; total hip BMD analysis consisted of 99 patients. IQR is given between 25th and 75th percentiles. aHigh glucocorticoid use is defined as a cumulative lifetime exposure of >5 g. bEarly RA defined as disease duration ⩽5 years. cVariable created to account for time difference (in months) between date of hand X-ray for hand DXR measurement and date of total hip or lumbar spine DXA for BMD measurement.